SecurityAZN / AstraZeneca Plc
InstitutionBay Colony Advisory Group, Inc D/b/a Bay Colony Advisors
Shares70
Value $ 2,000
Related 046353AB4 / Astrazeneca 5.9% Senior Notes 9/15/17
046353AF5 / Astrazeneca Plc 1.95% 09/18/19
046353AG3 / Astrazeneca Plc 4.00% 09/18/42
046353AA6 / Astrazeneca Plc 5.40% Notes 06/01/2014
046353AD0 / Astrazeneca Plc 6.45% Senior Notes 9/15/37
98934KAB6 / Zeneca Wilmington Inc Guaranteed Debentures 7% 11/15/23

Bay Colony Advisory Group, Inc D/b/a Bay Colony Advisors ownership in AZN / AstraZeneca Plc

August 09, 2018 - Bay Colony Advisory Group, Inc D/b/a Bay Colony Advisors has filed a 13F-HR form disclosing ownership of 70 shares of AstraZeneca Plc (NYSE:AZN) with total holdings valued at $2,000 USD as of June 30, 2018.

Other investors with positions similar to Bay Colony Advisory Group, Inc D/b/a Bay Colony Advisors include Hartford Financial Management Inc., Pflug Koory, Llc, Financial Gravity Companies, Inc., Financial Gravity Wealth, Inc., Lenox Wealth Advisors, Inc., and Amerivest Investment Management LLC.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR ASTRAZENECA PLC- SPONS ADR ADR 046353108 70 2 2 0 0.00

Related SEC Filings

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AstraZeneca SEC SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-02-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o (0-1)

Related News Stories

3 Large-Cap Pharma Stocks Performing Better Than Industry

2018-10-12 zacks
The Zacks Large-Cap Pharma industry, a 14 medical stock group, has gained 5.4% in the year so far. This industry also features among the top 9% of the 256 Zacks-ranked industries. (9-0)

J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

2018-10-12 zacks
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its blood thinner, Xarelto. The drug is now approved for reduction in risk of major cardiovascular (“CV”) events including CV death, myocardial infarction (“MI”) and stroke, in patients with chronic coronary or peripheral artery disease (CAD/PAD). (16-0)

PhaseBio IPO: Data To Be Released In 2018 And 2020

2018-10-12 seekingalpha
PhaseBio is a clinical-stage biopharmaceutical company developing treatments for orphan diseases. With a specialization on the cardiopulmonary space, the company has two product candidates, PB2452 and PB1046. (3-0)

Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

2018-10-11 zacks
On Oct 10, we issued an updated research report on Merrimack Pharmaceuticals, Inc. (MACK - Free Report) . (16-0)

Tencent reaches into London’s tech hub for Parkinson’s partner

2018-10-09 thestar.com.my
Digital analysis: Tencent Holdings Ltd is teaming with closely held Medopad Ltd to develop a system to remotely monitor patients with the severe movement disorder. — Reuters (4-0)



CUSIP: 046353108